Amgen reported revenue growth driven by strong performances from Enbrel and Filgrastim, while new product launches Prolia and XGEVA are off to a strong start. Despite higher operating expenses impacting net income, management reaffirmed 2011 guidance and expressed confidence in their investment strategy. Anticipation of detailed capital allocation plans, including potential dividends, may further boost investor sentiment in the short term.

[1]